[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1117237T1 - Συνθεσεις σταθερων τιακουμυκινων - Google Patents

Συνθεσεις σταθερων τιακουμυκινων

Info

Publication number
CY1117237T1
CY1117237T1 CY20161100177T CY161100177T CY1117237T1 CY 1117237 T1 CY1117237 T1 CY 1117237T1 CY 20161100177 T CY20161100177 T CY 20161100177T CY 161100177 T CY161100177 T CY 161100177T CY 1117237 T1 CY1117237 T1 CY 1117237T1
Authority
CY
Cyprus
Prior art keywords
thiacumykins
stable compositions
thiakumycins
formulations
difimicin
Prior art date
Application number
CY20161100177T
Other languages
English (en)
Inventor
Suketu Sanghvi
Mark Roach
Joseph F Zhou
Ping He
Michael Mittleberg
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY1117237T1 publication Critical patent/CY1117237T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Η παρούσα εφεύρεση αφορά φαρμακευτικές συνθέσεις ενός ή περισσότερων τιακουμυκινών, που παρουσιάζουν βελτιωμένη σταθερότητα, και μεθόδους θεραπείας χρησιμοποιώντας αυτού του είδους τα σκευάσματα. Τα σκευάσματα περιέχουν μία ή περισσότερες τιακουμυκίνες, όπως difimicin, και ένα ή περισσότερα αντιοξειδωτικά, όπως βουτυλιωμένο υδροξυτολουόλιο, και προαιρετικά ένα ή περισσότερα φαρμακευτικά αποδεκτά έκδοχα.
CY20161100177T 2007-01-19 2016-03-01 Συνθεσεις σταθερων τιακουμυκινων CY1117237T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88113707P 2007-01-19 2007-01-19
EP08724557.7A EP2121716B1 (en) 2007-01-19 2008-01-17 Compositions of stable tiacumicins

Publications (1)

Publication Number Publication Date
CY1117237T1 true CY1117237T1 (el) 2017-04-05

Family

ID=39641896

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100177T CY1117237T1 (el) 2007-01-19 2016-03-01 Συνθεσεις σταθερων τιακουμυκινων

Country Status (22)

Country Link
US (2) US20080176927A1 (el)
EP (1) EP2121716B1 (el)
JP (2) JP5635266B2 (el)
KR (1) KR101491729B1 (el)
CN (2) CN102015747A (el)
BR (1) BRPI0806713A8 (el)
CA (1) CA2676003C (el)
CY (1) CY1117237T1 (el)
DK (1) DK2121716T3 (el)
ES (1) ES2560669T3 (el)
HR (1) HRP20151438T1 (el)
HU (1) HUE028671T2 (el)
IL (1) IL199941A (el)
MX (1) MX2009007784A (el)
NZ (1) NZ578493A (el)
PL (1) PL2121716T3 (el)
PT (1) PT2121716E (el)
RU (1) RU2484829C2 (el)
SI (1) SI2121716T1 (el)
TW (1) TWI474820B (el)
WO (1) WO2008091518A1 (el)
ZA (1) ZA200905134B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
WO2011146624A2 (en) * 2010-05-18 2011-11-24 Optimer Pharmaceuticals, Inc. Methods of treating recurring bacterial infection
PE20130310A1 (es) * 2010-05-18 2013-04-06 Optimer Pharmaceuticals Inc Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos
CN105287473A (zh) * 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
US20140024609A1 (en) * 2011-02-04 2014-01-23 Optimer Pharmaceuticals ,Inc. Treatment of Bacterial Infections
ITMI20120560A1 (it) 2012-04-05 2013-10-06 Olon Spa Procedimento per la purificazione della tiacumicina b
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
PL3139932T3 (pl) * 2014-05-09 2019-02-28 Astellas Pharma Europe Ltd. Schemat leczenia dla związku-tiakumycyny
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物
CN112353774B (zh) * 2020-11-17 2022-08-23 浙江汇能生物股份有限公司 一种那西肽风味咀嚼片及其制备方法及其在犬魏氏梭菌病上的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05192094A (ja) * 1991-09-03 1993-08-03 Takeda Chem Ind Ltd 造粒組成物
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
DK1539977T3 (en) * 2002-07-29 2014-11-17 Optimer Pharmaceuticals Inc PREPARATION OF TIACUMICIN
US9211259B2 (en) * 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
CA2510465A1 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
CN101128114B (zh) * 2005-01-31 2012-03-28 浩鼎生技公司 18元环大环化合物及其类似物

Also Published As

Publication number Publication date
CA2676003C (en) 2012-04-10
BRPI0806713A2 (pt) 2011-09-13
RU2484829C2 (ru) 2013-06-20
EP2121716A1 (en) 2009-11-25
JP2010516677A (ja) 2010-05-20
KR20090107061A (ko) 2009-10-12
TWI474820B (zh) 2015-03-01
RU2009128612A (ru) 2011-02-27
ZA200905134B (en) 2013-08-28
US20130065844A1 (en) 2013-03-14
WO2008091518A1 (en) 2008-07-31
PT2121716E (pt) 2016-03-03
CN102015747A (zh) 2011-04-13
KR101491729B1 (ko) 2015-02-09
ES2560669T3 (es) 2016-02-22
IL199941A (en) 2016-02-29
JP5995331B2 (ja) 2016-09-21
DK2121716T3 (en) 2016-03-14
AU2008209623A2 (en) 2010-01-28
HUE028671T2 (en) 2016-12-28
PL2121716T3 (pl) 2016-04-29
CN105169396A (zh) 2015-12-23
JP2014205701A (ja) 2014-10-30
MX2009007784A (es) 2010-02-11
SI2121716T1 (sl) 2016-03-31
CA2676003A1 (en) 2008-07-31
TW200938187A (en) 2009-09-16
IL199941A0 (en) 2010-04-15
JP5635266B2 (ja) 2014-12-03
HRP20151438T1 (hr) 2016-01-29
BRPI0806713A8 (pt) 2017-04-18
NZ578493A (en) 2012-02-24
EP2121716A4 (en) 2013-06-12
AU2008209623A1 (en) 2008-07-31
US20080176927A1 (en) 2008-07-24
EP2121716B1 (en) 2015-12-09

Similar Documents

Publication Publication Date Title
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1124720T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY1121858T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτες και μεθοδοι χρησης αυτων
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
IL260127B (en) mek inhibitors and methods of using them
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
CY1118496T1 (el) Φαρμακεyτικες συνθεσεις
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
EA201170441A1 (ru) Терапевтические противовирусные пептиды
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1118396T1 (el) Θερμοπητικες αναισθητικες συνθεσεις
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
CY1112019T1 (el) Αγωνιστες υποδοχεων νιασινης, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι θεραπειας
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
PH12019501896A1 (en) Therapeutic dendrimers
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
ATE536172T1 (de) Ezetimibzusammensetzungen
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
CY1114977T1 (el) Στοματικες μορφες δοσολογιας της βενδαμουστινης
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
SE0402925D0 (sv) Novel Compounds